Elenagen’s mechanism of action diverges fundamentally from conventional chemotherapeutic paradigms. By encoding the multifunctional protein p62/SQSTM1, Elenagen influences the tumor microenvironment to mitigate chronic inflammation and enhance immune cell infiltration. This recalibration curbs tumor immune suppression and metastasis, leveraging the tumor cells’ intrinsic dependence on p62 as an immune target. Unlike therapies that merely intensify cytotoxic assault, Elenagen fosters an immunological milieu that supports endogenous anti-cancer processes, potentially revolutionizing therapeutic paradigms for ovarian and other solid tumors.

The randomized Phase II clinical trial, recently published in the International Journal of Gynecological Cancer, encompassed women with platinum-resistant disease exhibiting elevated CA-125 levels, a subgroup associated with the direst prognostic outcomes. In this rigorous study, participants receiving the Elenagen and gemcitabine regimen demonstrated a median overall survival exceeding 25 months—nearly doubling the approximately 13 months observed with chemotherapy alone. This staggering enhancement corresponds with an approximate 60% reduction in mortality risk, a transformative improvement that reframes expectations for this patient cohort.

Crucially, Elenagen’s therapeutic gains emerged without an accompanying increase in treatment-related toxicity. This favorable safety profile underscores the therapy’s tolerability and positions it as a promising adjunct without exacerbating the often burdensome side effects typical of cancer treatments. Equally remarkable are the long-term responders, some surviving years beyond predicted outcomes, underscoring the potential durability of Elenagen’s clinical benefit.

Insights gleaned from an unplanned treatment interruption due to geopolitical factors revealed a striking dose-duration response: longer exposure to Elenagen correlated with prolonged survival after discontinuation. These data suggest the current survival benefit estimates may be conservative, bolstering the rationale to extend therapy duration in ongoing and future trials. Plans are underway to evaluate Elenagen administration for up to 24 months, aiming to maximize therapeutic efficacy and patient outcomes in forthcoming U.S. and European studies.

The biological rationale for Elenagen’s efficacy extends beyond immunomodulation. The protein p62/SQSTM1 is integral to autophagy, oxidative stress responses, and oncogenic signaling pathways. Cancer cells’ overreliance on p62 creates a unique vulnerability; Elenagen’s plasmid DNA educates the immune system to recognize and target this protein, thus converting a tumor’s survival mechanism into an Achilles’ heel. This mechanism opens avenues not only for ovarian cancer but potentially other malignancies with p62 overexpression.

Dr. Alexander Shneider, CEO of CureLab Oncology and the inventor of Elenagen, emphasizes the evolutionary significance of this therapy. Originating as an experimental cancer vaccine, Elenagen has matured into a comprehensive adjuvant that addresses complex cancer biology via immune modulation and inflammation control. Its implications may transcend oncology, suggesting applications in diseases characterized by chronic inflammation and possibly aging—heralding a new class of DNA-based therapeutics with broad clinical potential.

Ovarian cancer remains one of the deadliest gynecologic cancers worldwide, affecting roughly one in eighty women during their lifetime. The recurrent nature of the disease, coupled with the development of platinum resistance, relegates patients to therapies with limited efficacy and significant side effects, often measured in mere months of survival. This stark reality underscores the urgent need for innovative treatments like Elenagen that challenge the existing therapeutic inertia.

With regulatory guidance and collaborative efforts alongside institutions such as the Gynecologic Oncology Group (GOG) Foundation, CureLab Oncology is advancing Phase II/III trials, aiming to solidify Elenagen’s clinical utility both in platinum-resistant ovarian cancer and aggressive breast cancer subtypes. These trials will incorporate comprehensive quality of life assessments, a critical dimension often underexplored yet paramount to patient-centered care, particularly for treatments modulating chronic inflammation.

The convergence of molecular innovation, immuno-oncology, and clinical rigor embodied by Elenagen heralds a hopeful horizon for patients enduring the formidable challenge of platinum-resistant ovarian cancer. By harnessing the intricate interplay of tumor biology and immune regulation, Elenagen exemplifies a transformative therapeutic paradigm—one that holds promise not only to extend life but also to enhance its quality.

In summary, Elenagen represents a groundbreaking development emerging from the intersection of advanced molecular medicine and immune modulation. Its capacity to double median survival without augmenting toxicity challenges conventional oncologic wisdom and sparks optimism for future therapies targeting tumor microenvironment and chronic inflammation. As clinical trials progress, the oncology community eagerly anticipates validation of these compelling results, potentially marking a pivotal shift in the management of refractory ovarian cancer.

Subject of Research: Investigational DNA therapy Elenagen (p62/SQSTM1-encoding plasmid) combined with gemcitabine for platinum-resistant ovarian cancer

Article Title: Randomized Phase II Study of P62/Sqstm1-Encoding Plasmid (Elenagen) In Combination With Gemcitabine for Platinum-Resistant Ovarian Cancer

News Publication Date: Prior to February 27, 2026 (conference presentation date)

Web References:

• CureLab Oncology: https://www.curelaboncology.com/
• International Journal of Gynecological Cancer article: https://www.international-journal-of-gynecological-cancer.com/article/S1048-891X(25)03580-7/fulltext

Image Credits: CureLab Oncology

Keywords: Ovarian cancer, platinum-resistant ovarian cancer, Elenagen, p62/SQSTM1, DNA therapy, immunotherapy, gemcitabine, tumor microenvironment, chronic inflammation, clinical trial, gynecologic oncology

Glioblastoma is an aggressive malignancy marked by rapid progression and a dismal median survival time of only eight months post-diagnosis. Traditional treatment modalities such as chemotherapy and surgery often yield limited efficacy. Immunotherapies, heralded for their revolutionary impact in multiple cancer types, have thus far failed to achieve significant success with glioblastoma due largely to the brain’s unique immune environment. The blood-brain barrier restricts immune cell infiltration, and the tumor microenvironment actively suppresses immune activity, leaving the cancer shielded from many therapeutic interventions.

TTFields therapy emerges as a novel biophysical approach, employing low-intensity, alternating electric fields to disrupt the mitotic processes of cancer cells. Delivered via strategically placed electrode arrays over the scalp, TTFields interfere with polarized intracellular components essential for cell division. This continual disruption impairs the ability of glioblastoma cells to proliferate, halting tumor growth. Moreover, patients typically wear the device for about 18 hours daily, maintaining consistent therapeutic exposure.

Beyond mere growth inhibition, the intriguing immunomodulatory effect of TTFields has captured scientific interest. The therapy appears to elevate the infiltration and persistence of tumor-fighting T cells—immune cells fundamental to cancer eradication—within and surrounding glioblastoma tissues. By fostering a more immunologically active tumor microenvironment, TTFields prime the battlefield for immunotherapy agents to exert more potent effects.

The immunotherapy employed in this study is pembrolizumab, a checkpoint inhibitor known for reinvigorating exhausted T cells by blocking the PD-1 immune checkpoint pathway. While pembrolizumab has had limited success as a standalone treatment for glioblastoma, its combination with TTFields aims to overcome the tumor’s immune evasion mechanisms by first recruiting and sustaining effector T cells locally.

Experimental evidence presented in the phase 2 clinical trial 2-THE-TOP demonstrated that administering TTFields alongside standard chemotherapy (temozolomide) and pembrolizumab led to a remarkable 70% increase in overall survival compared with historical controls treated with TTFields plus chemotherapy alone. Particularly notable was the robust benefit observed in patients with large, unresected tumors—a subgroup typically associated with poor outcomes.

In these patients, the augmented immune response likely stems from the presence of more tumor antigens, which, when combined with the disruptive electric fields, effectively ignite localized immune activation. The result is a more vigorous and sustained anti-tumor immune attack potentiated by pembrolizumab’s checkpoint blockade.

Dr. David Tran, chief of neuro-oncology at Keck Medicine and lead author, elucidates this synergy as a strategic “team sport” wherein TTFields destabilize tumor defenses, providing an opening for immunotherapy to successfully mobilize the immune system’s offensive arsenal. This dual-pronged assault overcomes the immunosuppressive barriers of glioblastoma, offering a therapeutic breakthrough.

The study enrolled 31 patients newly diagnosed with glioblastoma who had completed chemoradiation. Twenty-six participants received the tripartite treatment regimen, with six to twelve months of chemotherapy, continuous TTFields application up to 24 months, and pembrolizumab infusions every three weeks beginning after the initial chemotherapy cycles. Outcomes revealed extended survival times and elevated T cell activity, underscoring the clinical and immunological potential of the combined treatment.

Importantly, the research also opens questions about the role of surgical tumor resection in the context of these therapies. Patients unable to undergo tumor removal appeared to benefit even more significantly, suggesting that the presence of the tumor mass serves as a substrate that TTFields and immunotherapy can exploit to launch a heightened immune response. Future investigations aim to clarify this relationship and optimize treatment protocols accordingly.

Keck Medicine is now advancing this line of inquiry in a multicenter phase 3 clinical trial enrolling over 700 glioblastoma patients worldwide. This pivotal study, led by Dr. Tran as the steering committee chair, will rigorously assess the efficacy and safety of the combined TTFields, pembrolizumab, and chemotherapy approach across diverse patient populations and tumor resection statuses.

The promise of TTFields lies not only in its direct cytostatic effects but also its capacity to reshape the neuro-oncological immunological landscape—a key barrier that has thwarted many previous immunotherapeutic attempts. Its integration into comprehensive treatment regimens may ultimately redefine standards of care for glioblastoma, a cancer that for decades has defied effective longue durée management.

With ongoing research and clinical validation, TTFields combined with immunotherapy represents a beacon of hope, signaling a transformative shift toward harnessing physical and immune-mediated strategies in unison to combat one of the most formidable brain tumors known to medicine.

Subject of Research: People

Article Title: Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study

News Publication Date: 3-Jun-2025

Web References:

• Clinical Trial NCT03405792: https://clinicaltrials.gov/study/NCT03405792
• Clinical Trial NCT06556563: https://clinicaltrials.gov/study/NCT06556563

References:
Tran DD, Chen D, Le S, et al. Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study. Med. 2025; doi:10.1016/j.medj.2025.100708.

Image Credits: Image used with permission from Novocure GmbH

Keywords: Glioblastomas, Brain cancer, Cancer, Immunotherapy, Health and medicine